An observational study in HIV/AIDS, sponsored by Guangzhou 8th People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-06-15.
Sponsored by Guangzhou 8th People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Acquired Immunodeficiency Syndrome by Guangzhou 8th People's Hospital — 10 open to participants now, 10 under way, none of them phase 3. Acquired Immunodeficiency Syndrome · Guangzhou 8th People's Hospital.
Among the 11 studies in Acquired Immunodeficiency Syndrome by Guangzhou 8th People's Hospital, this one is the only one that started in 2022, is one of 8 observational ones, and was the 7th registered.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →10 of the 11 studies in Acquired Immunodeficiency Syndrome by Guangzhou 8th People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–60
By country, each count listing its studies:
Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 450 is above the median of 289 across 504 observational studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 20 across the 3 interventional studies, 350 across the 8 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Guangzhou 8th People's Hospital is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Acquired Immunodeficiency Syndrome by Guangzhou 8th People's Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ainuovirine is the third generation of non nucleoside reverse transcriptase inhibitors(NNRTIs), for the treatment of HIV-1 infected adults. The existing clinical studies show that Ainuovirine is safe and potent, it solves the problem from the first-generation NNRTIs such as Efavirenz with large side effects and the second-generation like Rilpivirine not suitable for high viral load, but there are no relevant data or reports on the efficacy and safety of Ainuovirine in HIV-infected patients in China so far. This project aims to explore the efficacy and safety of ART regimens containing Ainuovirine for HIV-infected patients in real clinical environment, in further to guide clinical application.
This study is an open-label, multicentered, single-arm and phase IV clinical trial.
450 HIV-infected patients who received Ainuovirine regimen (150mg, oral, qd) were included. At day 1 (1st collection as day 1), 3rd, 6th, 9th, 12th month, the rate of viral suppression and CD4+T cell count were calculated against baseline. In addition, the safety and drug compliance were also monitored.
Other indicators:
Demographic data (including gender, ethnicity, age, height, education level, occupation, route of infection), past medical history, smoking history, drug abuse history, hepatitis B markers, hepatitis C antibody, B ultrasound, chest X-ray, electrocardiogram, pregnancy test (Females of childbearing age): Day 1 (1st collection as Day 1), 1 time in total.
Vital signs (heart rate, blood pressure), body weight: 5 times on day 1 (the 1st collection was taken as day 1), 3rd, 6th, 9th, and 12th months.
Patients who are prescribed to take including Ainuovirine regimen,because they are unable to tolerate the side-effect of or are not fit for the firstline free regimen in China,according to clinical judgment, no matter of the HIV-RNA viral loads and CD4 cell counts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of infection 18-60 years old Patients who are prescribed to take Ainuovirine regimen . Sign
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
These cases were given the regimen including Ainuovirine (150mg, oral,qd)
Drug: Ainuovirine
The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.
Virus suppression rate
ratio of HIV1-RNA \< 20 copies/mL at 48 weeks of treatment
Time frame: 48 weeks
Adverse events
Any adverse events reported during the observational period
Time frame: 48 weeks
Immune reconstitution indicators
CD4 cell count, CD4 +/ CD8 + ratio (baseline to 48 weeks)
Time frame: 48 weeks
Drug compliance
To explicit the number of people who have completed the treatment
Time frame: 48 weeks
Plan to share: No
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Dec 2024, 31 months after the start.
Of 165 non-industry observational studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 83. This study's planned 31 months is below that.
Counting every sponsor, half of 177 studies reached it within 44 months; a quarter within 19 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome →
Guangzhou 8th People's Hospital